Clinical Study of Translocated Internal Limiting Membrane Flap Reposition for the Treatment of Idiopathic Macular Hole

Inclusion Criteria: Participants who can understand the purpose of this clinical trial, volunteer to participate, sign an informed consent form, and can complete the postoperative follow-up on time. Participants diagnosed with idiopathic macular hole (IMH). Based on OCT scans, the minimum horizontal diameter of the macular hole is >500 and <900 µm. Participants with an axial length <26.0mm and a myopic degree lower than 6D. For participants with bilateral macular holes, the eye with a larger hole diameter will be included. Exclusion Criteria: Patients with the following retinal disorders: age-related macular degeneration, epi-macular membrane neovascularization, non-macular retinal tears, lesions of the retinal pigment epithelium and choroid, inherited or degenerative retinal diseases, optic neuropathies, retinal vascular diseases; patients with large macular holes accompanied by retinal detachment; Patients with high myopia (axial length ≥ 26.0mm and myopia exceeding 6D); Patients with a history of ocular trauma or retinal laser treatment; Patients with glaucoma, ocular infections, inflammations, tumors, corneal diseases, or amblyopia; Patients with contraindications to vitrectomy; Patients with severe or unstable systemic diseases; Patients with a fasting blood glucose level ≥ 9mmol/L before surgery; Patients who participated in other clinical trials involving drugs or medical devices within 30 days prior to screening; Patients with a history of intraocular surgery within 3 months prior to screening; Patients with reduced visual function or vision in the contralateral eye as determined by the investigator; Patients who are not considered suitable for enrollment by the investigator for other reasons.